Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02220218 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02220218 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 2 participants.
The verdict
NCT02220218, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study to evaluate the bioequivalence (is the amount same in both the pills) of metformin component of the canagliflozin and metformin immediate release (IR) fixed dose combination (FDC) tablet compared with the metformin IR tablet co-administered with canagliflozin tablet in healthy fed and fasted participants.
Interventions
- DRUG Canagliflozin
- DRUG Metformin IR
- DRUG Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02220218
The ClinicalTrials.gov registry entry for NCT02220218 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Canagliflozin is the first listed.
NCT02220218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02220218 about?
NCT02220218 is a clinical study titled "Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants". The purpose of this study to evaluate the bioequivalence (is the amount same in both the pills) of metformin component of the canagliflozin and metformin immediate release (IR) fixed dose combination (FDC) tablet compared with the metformin IR tablet co-administered with canagliflozin tablet in heal...
What is the current status of trial NCT02220218?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2014-08. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02220218?
The interventions under investigation include: Canagliflozin (DRUG), Metformin IR (DRUG), Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC) (DRUG).
Who is sponsoring clinical trial NCT02220218?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.